Home / Deep Research / Benign Neonatal Seizures

Benign Neonatal Seizures

Benign Neonatal Seizures: Manual Deep Research Summary

2026-05-13
⚠️ Fallback MONDO:0016027 Model: n/a 6 citations

Benign Neonatal Seizures: Manual Deep Research Summary

Disease-level modeling decision

Benign neonatal seizures is modeled as one disease-level entry covering the autosomal-dominant KCNQ2- and KCNQ3-related forms of self-limited familial neonatal epilepsy. Two molecular subtypes are exposed via has_subtypes, each grounded to the corresponding MONDO term:

  • KCNQ2-BFNS → MONDO:0007365 (seizures, benign familial neonatal, 1; xref OMIM:121200).
  • KCNQ3-BFNS → MONDO:0007366 (seizures, benign familial neonatal, 2; xref OMIM:121201).

The much more severe KCNQ2-related developmental and epileptic encephalopathy (KCNQ2-DEE) is intentionally excluded from this entry — the disease description notes the boundary so future curators do not collapse the two clinical entities.

Inheritance and penetrance

ORPHA:1949 lists autosomal dominant inheritance for self-limited neonatal epilepsy. The original KCNQ2 paper (PMID:9425895) frames the condition as "a dominantly inherited disorder of newborns."

The ILAE Genetic Literacy review (PMID:36939707) is the strongest source for incomplete penetrance and de novo inheritance:

"incomplete penetrance and de novo inheritance occur."

This justifies tagging both KCNQ2 and KCNQ3 Inheritance blocks in the genetic section with penetrance: INCOMPLETE.

Pathophysiology: KCNQ2/KCNQ3 LOF → M-current attenuation → transient neonatal hyperexcitability

The mechanistic chain is documented across the cached literature:

  1. KCNQ2 and KCNQ3 subunits form the neuronal M-channel. PMID:9836639: "It is concluded that both these subunits contribute to the native M-current."
  2. The M-current sets subthreshold excitability. PMID:9836639: "The M-current regulates the subthreshold electrical excitability of many neurons, determining their firing properties and responsiveness to synaptic input."
  3. Heterozygous LOF variants in KCNQ2/3 reduce M-current density and cause BFNC. PMID:9425895: "This finding in BFNC provides additional evidence that defects in potassium channels are involved in the mammalian epilepsy phenotype." PMID:9425900 maps a KCNQ3 pore-region missense variant co-segregating with BFNC.
  4. Network-level hyperexcitability is transient and remits. PMID:36939707: "Seizures tend to remit during infancy or early childhood and are therefore called 'self-limited'."

The disorder YAML therefore exposes two atomic pathophysiology nodes connected by a downstream edge:

  • KCNQ2/KCNQ3 K+ Channel Loss-of-Function and M-Current Attenuation (central_effector) — captures the molecular function (GO:0005249, DECREASED) and process (GO:0086009 membrane repolarization, DECREASED).
  • Neonatal Neuronal Hyperexcitability (downstream_phenotype) — captures the network-level firing increase (GO:0019228 neuronal action potential, INCREASED), localized to cerebral cortex, with a further downstream edge to the clinical Focal-onset Seizure phenotype.

This decomposition deliberately avoids the bundled "channelopathy → seizures" anti-pattern flagged in prior dismech reviews.

Clinical phenotypes

ORPHA:1949 supplies a curated HPO-frequency table that I have mapped directly into the phenotypes block:

  • Neonatal seizure (HP:0032807) — Very frequent (99–80%)
  • Focal-onset seizure (HP:0007359) — Very frequent
  • Focal tonic seizure (HP:0011167) — Very frequent
  • Focal clonic seizure (HP:0002266) — Very frequent
  • Apnea (HP:0002104) — Frequent (79–30%)
  • Focal EEG discharges with secondary generalization (HP:0011188) — Very frequent

PMID:28926830 (the multicenter aEEG case series) supports the focal tonic semiology with characteristic apnea and desaturation.

Diagnosis and targeted therapy

PMID:36939707 supports molecular genetic testing (MAXO:0000533) as part of the diagnostic workup. PMID:28926830 and PMID:37827512 jointly support amplitude-integrated EEG (aEEG) as an early-recognition tool that enables targeted carbamazepine therapy before genetic confirmation:

"Recognition of the distinctive ictal aEEG pattern in the NICU allowed early and effective targeted therapy with CBZ in four neonates, well before genetic results became available." (PMID:37827512)

Carbamazepine (CHEBI:3387) is exposed as a specific treatment using the treatment_term = MAXO:0000167 (anticonvulsant agent therapy) + therapeutic_agent = CHEBI:3387 pattern, with a target_mechanisms link back to the Neonatal Neuronal Hyperexcitability node. The Sodium-channel-blocking Antiseizure Medication Therapy treatment generalizes this to the drug class.

Phenobarbital is recognized in clinical practice as an empiric first-line neonatal antiseizure agent before genetic confirmation, but is intentionally not modeled as a targeted therapy because it does not act on the KCNQ2/3 mechanism; the YAML keeps the mechanistic focus on sodium-channel blockers, per the precision- medicine framing in PMID:28926830.

References used

  • PMID:9425895 — KCNQ2 discovery in BFNC.
  • PMID:9425900 — KCNQ3 pore-region missense in BFNC.
  • PMID:9836639 — KCNQ2/KCNQ3 as molecular correlates of the M-channel.
  • PMID:28926830 — Distinctive ictal aEEG pattern in KCNQ2 neonatal epilepsy; precision medicine with Na+-channel blockers.
  • PMID:36939707 — ILAE Genetic Literacy review of self-limited familial neonatal/infantile epilepsies; incomplete penetrance and de novo inheritance.
  • PMID:37827512 — Carbamazepine targeted therapy guided by aEEG pattern recognition.
  • ORPHA:1949 — Orphanet structured-database record (HPO frequencies, gene-disease table, MONDO/OMIM cross-references, inheritance).